Evidence map›Paper›PMID 40123511›Full record

Trial reportStroke2025

Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial.

Adham Shawkat, Andrew D Barreto, Joseph P Broderick, Colin P Derdeyn, James C Grotta, Pooja Khatri, Stephanie Pizzella, Ian Rines, Akash Roy, Alastair Wilson and 2 more

Registry-linked trialAbstract readRandomized Controlled TrialComparative StudyClinical Trial, Phase III
In one paragraph

Trial report in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03735979 (Multi-arm Optimization of Stroke Thrombolysis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03735979 phase3completednot on this map

Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke

TypeinterventionalSponsorWashington University School of MedicineRan2019 to 2024Enrolled514ConditionsAcute Ischemic StrokeArmsArgatroban, Eptifibatide, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adham ShawkatSchool of Medicine, University of Louisville, KY (A.S.).ORCID 0009-0005-1605-6695
Andrew D BarretoDepartment of Neurology, University of Texas Health Science Center, Houston (A.D.B.).
Joseph P BroderickDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (J.P.B., P.K.).ORCID 0000-0002-7323-7709
Colin P DerdeynDepartment of Radiology, University of Virginia, Charlottesville (C.P.D.).ORCID 0000-0002-5932-2683
James C GrottaClinical Institute for Research and Innovation, Memorial Hermann Hospital, Houston, TX (J.C.G.).ORCID 0000-0002-3667-4248
Pooja KhatriDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (J.P.B., P.K.).ORCID 0000-0002-7344-8266
Stephanie PizzellaDepartment of Emergency Medicine, Washington University, St. Louis, MO (S.P., O.M.A.).ORCID 0009-0009-5263-7015
Ian RinesDepartment of Public Health Sciences, Medical University of South Carolina, Charleston (I.R., A.R.).ORCID 0009-0009-7604-3094
Akash RoyDepartment of Public Health Sciences, Medical University of South Carolina, Charleston (I.R., A.R.).ORCID 0000-0001-6506-6156
Alastair WilsonInstitute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (A.W.).
Max WintermarkDepartment of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston (M.W.).ORCID 0000-0002-6726-3951
Opeolu M AdeoyeDepartment of Emergency Medicine, Washington University, St. Louis, MO (S.P., O.M.A.).ORCID 0000-0001-8666-5369

Funding

NSTN National Clinical Coordinating CenterU01NS086872 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Pooja Khatri · 2013 to 2026
$32.3M
Multi-arm Optimization of Stroke Thrombolysis (MOST) Stroke TrialU01NS100699 · NINDS · WASHINGTON UNIVERSITY · PI ADEOYE, OPEOLU M, BARRETO, ANDREW D · 2018 to 2021
$18.8M
Workshop to Identify Collaborative Project(s) for the NIH StrokeNet and the Japan NEtwork for Clinical Stroke Trials (NECST)U01NS087748 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Catherine R. Dillon, Jordan J. Elm · 2014 to 2026
$14.1M
Mid-America Regional Coordinating Center (MARCC)U24NS107230 · NINDS · WASHINGTON UNIVERSITY · PI Andria Lee Ford, Peter David Panagos · 2018 to 2026
$2.8M
NINDS NIH HHS U01 NS086872NINDS NIH HHS U01 NS087748NINDS NIH HHS U01 NS100699NINDS NIH HHS U24 NS107230
6 · The paper itself

Abstract

backgroundThe modified Rankin Scale (mRS) is a key measure of functional outcomes in stroke trials. To minimize variability, structured tools like the Rankin Focused Assessment and central adjudication are recommended. This study compares local versus centrally adjudicated mRS scores in the MOST trial (Multi-Arm Optimization of Stroke Thrombolysis).

methodsMOST was a phase 3, single-blind, randomized trial evaluating argatroban, eptifibatide, or placebo in addition to intravenous thrombolysis. The primary outcome, 90-day mRS score, was gathered through in-person video recordings by blinded local personnel. Recordings were sent to central adjudicators for final scoring. As in-person visits became limited due to SARS-CoV-2, remote interviews were allowed. We hypothesized that local mRS scores would be moderately associated with central scores. Fleiss-Cohen quadratic weighted κ statistics were used to determine the strength of agreement.

resultsOut of 514 participants, 378 had recorded visits available (121 in-person video, 157 remote video, 100 remote audio). Local assessors were blinded 96.8% of the time and 85.4% of visits used the Rankin Focused Assessment. Overall agreement between local and central mRS scores was excellent (weighted κ, 0.87 [95% CI, 0.83-0.90]). A nonsignificant decrease in strength of agreement was noted for those with a nonzero baseline mRS (mRS score=0, 0.87 [95% CI, 0.84-0.91] versus mRS score >0, 0.80 [95% CI, 0.68-0.91]). Trial conclusions were unchanged when utilizing the local mRS versus central adjudication.

conclusionsLocal mRS scores demonstrated strong agreement with central scores across all assessment modes. With blinded end point assessments, central mRS adjudication in acute stroke trials may not be necessary. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03735979.

Indexed as

StrokeThrombolytic TherapyAgedArginineCOVID-19FemaleHumansMaleMiddle AgedPipecolic AcidsSingle-Blind MethodSulfonamidesTreatment OutcomeargatrobanArgininePipecolic AcidsSulfonamidesargatrobanclinical trialseptifibatideischemic strokethrombolysis

Identifiers

PMID40123511
PMCPMC12037301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.